Sean Pinney, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1174524474
Payments from drug & device makers
Across 349 payments — averaging $1187.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Transmedics, Inc.$172K
- Abbott$115K
- Procyrion, Inc.$29K
- Ancora Heart, Inc.$29K
- Nuwellis, Inc.$22K
- United Therapeutics Corporation$15K
- plus $31K from 27 others
Across 10 payments — averaging $2769.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$28K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Transmedics, Inc. | 18 | $171,658 |
| Abbott | 128 | $114,898 |
| Procyrion, Inc. | 7 | $29,420 |
| Ancora Heart, Inc. | 36 | $29,358 |
| Nuwellis, Inc. | 12 | $22,366 |
| United Therapeutics Corporation | 13 | $15,171 |
| Boehringer Ingelheim International GmbH | 35 | $7,607 |
| Edwards Lifesciences | 5 | $5,000 |
| Merck | 16 | $4,422 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,532 |
| Impulse Dynamics (USA) Inc. | 3 | $1,870 |
| Novartis | 6 | $1,433 |
| Medicure Pharma Inc. | 1 | $1,200 |
| Cvrx, Inc. | 8 | $1,027 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $1,017 |
| Medtronic(2 entities) | 16 | $994 |
| Boston Scientific | 2 | $919 |
| Sanofi-aventis U.S. LLC | 3 | $882 |
| Abiomed | 5 | $576 |
| Sensible Medical Innovations Inc | 4 | $305 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $133 |
| AstraZeneca | 3 | $125 |
| Alnylam Pharmaceuticals Inc. | 3 | $104 |
| Scpharmaceuticals Inc. | 3 | $90 |
| Pfizer | 2 | $44 |
| Bridgebio Pharma, Inc. | 2 | $35 |
| ZOLL Circulation Inc | 1 | $35 |
| Boehringer Ingelheim | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Sensible Medical Innovations Ltd | 1 | $23 |
| Analog Devices Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
How this compares
$414,349 in reported general payments places this provider in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in New York
- Mathew MaurerNew York$5M
- Evelyn HornNew York$2.9M
- Johanna ContrerasNew York$1.4M
- Parag GoyalNew York$1.1M
- Nir UrielNew York$884K
- Tajinderpal SaraonNew York$618K
- Kelly AxsomNew York$502K
- Yevgeniy BrailovskyNew York$339K
- James YoussefNew York$287K
- Alex ReyentovichNew York$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.